Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6416939 | 0.87 | — | — | |
| SCHEMBL9240941 | 0.80 | MEN1 (0.31) | POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL14110147 | 0.80 | — | — | |
| SCHEMBL34475630 | 0.80 | — | — | |
| SCHEMBL18319547 | 0.77 | — | — | |
| SCHEMBL7257991 | 0.76 | MEN1 (0.33) | POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL12354430 | 0.73 | — | — | |
| SCHEMBL9257505 | 0.71 | — | — | |
| SCHEMBL16835496 | 0.70 | TET3 (0.30) | KMT2A | |
| SCHEMBL10681139 | 0.70 | MEN1 (0.31) | POLBMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038249-B1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM SPA (IT) | 2013-09-11 | — | — | EP | claimed |
| US-8143443-B2 | Process for preparing gabapentin | ZACH SYSTEM S.P.A. (IT) | 2012-03-27 | — | — | US | claimed |
| US-20100029983-A1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM S.P.A. (IT) | 2010-02-04 | — | — | US | claimed |
| EP-2038249-A1 | PROCESS FOR PREPARING GABAPENTIN | ZaCh System S.p.A. (IT) | 2009-03-25 | — | — | EP | claimed |
| WO-2008004115-A1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM S.P.A. (IT) | 2008-01-10 | — | — | WO | claimed |
| US-4229367-A | Preparation of trans-4-alkyl-cyanoarylcyclohexanes | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1980-10-21 | — | — | US | claimed |
| JP-62141003-A | — | — | None | — | — | JP | disclosed |
| JP-62141004-A | — | — | None | — | — | JP | disclosed |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-101484413-B | Process for preparing gabapentin | ZACH SYSTEM SPA | 2014-05-14 | — | — | CN | disclosed |
| EP-2038249-B1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM SPA (IT) | 2013-09-11 | — | — | EP | disclosed |
| EP-2038249-B1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM SPA (IT) | 2013-09-11 | — | — | EP | disclosed |
| WO-2008004115-A1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM S.P.A. (IT) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008004115-A1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM S.P.A. (IT) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008004115-A1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM S.P.A. (IT) | 2008-01-10 | — | — | WO | disclosed |
| EP-0281121-B1 | 1-(1-ARYL-2-HYDROXY-ETHYL)-IMIDAZOLES AND THEIR SALTS, PROCESSES FOR THEIR PREPARATION, DRUGS CONTAINING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-04-29 | — | — | EP | disclosed |
| US-4999352-A | Antidepressants or fungicides | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-03-12 | — | — | US | disclosed |
| JP-S62141003-A | POLYVINYL ALCOHOL ACETALIZED WITH UNSATURATED CYCLIC CARBOALDEHYDE | SEKISUI CHEM CO LTD | 1987-06-24 | — | — | JP | disclosed |
| JP-S62141004-A | POLYVINYL ALCOHOL ACETALIZED WITH CYCLOHEXANECARBOALDEHYDE AND ALKYLCYCLOHEXANECARBOALDEHYDE | SEKISUI CHEM CO LTD | 1987-06-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029983-A1 | PROCESS FOR PREPARING GABAPENTIN | GABRB1, GABRG1, OGDH | POLB 3192/4885MEN1 1451/4885KMT2A 4114/4885 |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | PTPN1, PTPN9, PTPN7 | POLB 4196/4885MEN1 2874/4885KMT2A 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.